Ultragenyx Gains 10% on FDA Approval for Fayuvi Gene Therapy

Ultragenyx Pharmaceutical shares climbed 10% following the Food and Drug Administration's approval of Fayuvi, establishing the product as the first authorized gene therapy for pediatric patients with Sanfilippo syndrome type A. The regulatory milestone marks a significant therapeutic shift for a rare inherited condition that previously lacked any disease-modifying treatment options, according to an Investing.com report.

How Fayuvi Delivers the SGSH Gene

Fayuvi is administered as a one-time intravenous gene therapy designed to address the root genetic cause of mucopolysaccharidosis type IIIA, commonly known as Sanfilippo syndrome type A. The treatment utilizes a modified adeno-associated virus serotype 9 vector to transport a working copy of the SGSH gene into patient cells.

This delivery mechanism enables cellular production of sulfamidase, the enzyme that patients with this condition lack. Without this enzyme, cellular waste accumulates progressively, causing severe damage to the brain and nervous system over time.

Clinical Safety and Regulatory Warnings

While the therapy offers a novel mechanism to target the underlying disease progression, clinical evaluation identified notable safety risks that regulators flagged in the approval documentation. According to the Investing.com coverage, the FDA highlighted a specific risk of thrombotic microangiopathy alongside a potential long-term risk of tumor development linked to genetic material integration.

Common adverse reactions observed during clinical testing included:

• Liver enzyme increases
• Nausea and vomiting
• Fever and decreased appetite
• Lower white blood cell and platelet counts

Market Valuation and Financial Context

In the public markets, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $14.65, up 0.96% from its previous close of $14.51, according to Finnhub market data as of September 21, 2026. The 10% surge reflects investor reaction to the commercial validation of the company's rare disease pipeline and the opening of an addressable market where zero therapeutic alternatives previously existed.

What Sanfilippo Syndrome Type A Means for Patients

Sanfilippo syndrome type A is a debilitating genetic disorder characterized by severe neurodegeneration, developmental regression, and significantly shortened life expectancy, typically manifesting in early childhood. The availability of Fayuvi provides the first targeted intervention designed to alter this clinical trajectory, shifting the treatment paradigm from purely palliative supportive care to disease-modifying genetic delivery.